tiprankstipranks
Shanghai Kindly Medical Instruments Co., Ltd. Class H (HK:1501)
:1501
Hong Kong Market
Want to see HK:1501 full AI Analyst Report?

Shanghai Kindly Medical Instruments Co., Ltd. Class H (1501) AI Stock Analysis

2 Followers

Top Page

HK:1501

Shanghai Kindly Medical Instruments Co., Ltd. Class H

(1501)

Select Model
Select Model
Select Model
Neutral 69 (OpenAI - 5.2)
Rating:69Neutral
Price Target:
HK$42.00
▲(43.34% Upside)
Action:ReiteratedDate:04/25/26
The score is driven primarily by solid underlying financial performance (growth and strong 2025 cash flow rebound) tempered by higher leverage and margin compression. Technicals add support with price above major moving averages and positive momentum, while valuation is only moderate given the ~20.8 P/E and no dividend yield data.
Positive Factors
Revenue Growth
Accelerating revenue growth to 12.7% in 2025 reflects durable end-market demand and expanding market penetration in medical instruments. Sustained top-line expansion supports scale economies, funds R&D and commercialization, and provides a multi-quarter tailwind to cash flow and strategic investments.
Negative Factors
Rising Leverage
Total debt increasing to ~716m from ~244m materially raises leverage and debt-to-equity, reducing financial flexibility. Higher interest and refinancing exposure magnify sensitivity to earnings swings and constrains strategic spending or M&A capacity in the 2–6 month horizon and beyond.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Accelerating revenue growth to 12.7% in 2025 reflects durable end-market demand and expanding market penetration in medical instruments. Sustained top-line expansion supports scale economies, funds R&D and commercialization, and provides a multi-quarter tailwind to cash flow and strategic investments.
Read all positive factors

Shanghai Kindly Medical Instruments Co., Ltd. Class H (1501) vs. iShares MSCI Hong Kong ETF (EWH)

Shanghai Kindly Medical Instruments Co., Ltd. Class H Business Overview & Revenue Model

Company Description
Shanghai Kindly Medical Instruments Co., Ltd. engages in the research and development, manufacture, and sale of cardiovascular interventional medical devices in Mainland China, Europe, the United States, and internationally. The company offers int...
How the Company Makes Money
null...

Shanghai Kindly Medical Instruments Co., Ltd. Class H Financial Statement Overview

Summary
Solid 2025 revenue growth (12.7%) and healthy profitability (~20.5% net margin) are positives, supported by a rebound in operating and free cash flow in 2025. Offsetting factors include margin compression versus earlier years, a sharp 2025 increase in leverage (debt up to ~716m from ~244m), and historically volatile free cash flow (negative in 2021–2023).
Income Statement
74
Positive
Balance Sheet
67
Positive
Cash Flow
61
Positive
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.04B851.95M752.84M585.88M464.68M
Gross Profit620.31M537.66M438.07M332.49M275.75M
EBITDA316.70M255.43M225.88M159.99M168.81M
Net Income213.12M191.91M156.46M131.71M142.96M
Balance Sheet
Total Assets3.13B2.26B2.03B1.83B1.62B
Cash, Cash Equivalents and Short-Term Investments651.85M554.51M434.40M528.27M640.55M
Total Debt716.26M243.69M94.78M48.83M13.40M
Total Liabilities1.04B473.39M351.25M273.23M183.63M
Stockholders Equity2.00B1.77B1.65B1.51B1.40B
Cash Flow
Free Cash Flow278.17M59.80M-53.05M-62.75M-205.07M
Operating Cash Flow340.98M225.54M178.15M180.46M72.76M
Investing Cash Flow-491.99M-187.31M-283.81M-316.18M-268.08M
Financing Cash Flow263.40M56.97M8.06M9.72M-31.07M

Shanghai Kindly Medical Instruments Co., Ltd. Class H Technical Analysis

Technical Analysis Sentiment
Positive
Last Price29.30
Price Trends
50DMA
32.08
Positive
100DMA
31.40
Positive
200DMA
30.33
Positive
Market Momentum
MACD
2.29
Negative
RSI
68.54
Neutral
STOCH
74.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1501, the sentiment is Positive. The current price of 29.3 is below the 20-day moving average (MA) of 34.38, below the 50-day MA of 32.08, and below the 200-day MA of 30.33, indicating a bullish trend. The MACD of 2.29 indicates Negative momentum. The RSI at 68.54 is Neutral, neither overbought nor oversold. The STOCH value of 74.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1501.

Shanghai Kindly Medical Instruments Co., Ltd. Class H Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
HK$5.68B8.3616.76%3.65%11.07%48.01%
74
Outperform
HK$1.77B19.043.68%7.46%7.11%-34.66%
72
Outperform
HK$25.88B20.0721.02%0.63%6.10%16.67%
69
Neutral
HK$8.26B20.7511.20%25.24%7.29%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
47
Neutral
HK$529.42M-7.56-24.95%-1.09%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
38.66
12.16
45.89%
HK:1358
PW Medtech Group Ltd.
1.15
0.20
21.05%
HK:0876
Kaisa Health Group Holdings Limited
0.11
0.08
275.00%
HK:3600
Modern Dental Group Limited
6.08
2.08
52.11%
HK:2276
Shanghai Conant Optical Co. Ltd. Class H
48.60
24.96
105.58%

Shanghai Kindly Medical Instruments Co., Ltd. Class H Corporate Events

Shanghai INT Medical Sets 2026 AGM to Approve Results, Budget and Share Buyback Mandate
Apr 22, 2026
Shanghai INT Medical Instruments Co., Ltd. has called its annual general meeting for 28 May 2026 in Shanghai, where shareholders will review reports from the board and supervisory committee, the 2025 annual report, audited group financial statemen...
Shanghai Kindly Medical Declares Final 2025 Dividend for H Shareholders
Mar 27, 2026
Shanghai Kindly Medical Instruments Co., Ltd. has declared a final ordinary cash dividend of RMB 0.23 per share for the financial year ended 31 December 2025, equivalent to HKD 0.26 per H share based on an exchange rate of RMB 1 to HKD 1.135. The ...
Shanghai Kindly Medical Posts Double-Digit Profit Growth on Rising Interventional Device Sales
Mar 27, 2026
Shanghai Kindly Medical Instruments Co., Ltd. reported strong growth for the year ended 31 December 2025, with revenue rising 25.06% year on year to RMB1.07 billion, driven by an expanded customer base and business combinations. Sales of intervent...
Shanghai INT Medical Instruments Sets Board Meeting to Approve 2025 Results and Consider Dividend
Mar 17, 2026
Shanghai INT Medical Instruments Co., Ltd., a Hong Kong-listed Chinese medical device manufacturer, announced that its board includes a mix of executive, non-executive and independent non-executive directors led by Chairman Dr. Liang Dongke. The c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 25, 2026